Merit-Based Incentive Payment System (MIPS) for General Oncology

Work with Able Health to track performance for MIPS and submit data to CMS

The first performance period for the Medicare Merit-Based Incentive Payment System (MIPS) began January 1, 2017. With CMS combining multiple Medicare Part B programs into one performance-based payment system, provider organizations must stay on top of requirements in order to maintain and increase Medicare payments over the next decade. Able Health can greatly reduce the administrative cost of participating in MIPS and help you improve performance in order to maximize your payment adjustment.MIPS is a budget-neutral program with an additional $500 million pool allocated for exceptional performers. Providers who prepare ahead of their peers will be able to earn higher payment adjustments and bonuses

MIPS in a Box

Track performance using patient-level data

Able Health calculates quality measures using patient-level data from EHRs, claims, and other sources. Easily enter performance data for Cost, Advancing Care Information, and Improvement Activities to track your MIPS Composite Performance Score over time. If you are participating in a MIPS APM, Able Health can replace MIPS measures with applicable measures from your APM.

Educate your team about MIPS as they use the product

In-app tooltips and articles explain how measures are calculated, how to form a valid quality measure set, how the Composite Score is calculated, and more—when and where you need it. Our guidance can reduce the cost of training, time to research requirements, and the negative impact of potential mistakes.

Improve performance with care tools

Identify clinicians and patients who need your attention—and take action to improve performance. Deliver scorecards to clinicians, including patient-level measure results and EHR source records. Generate call lists of patients who need care, including specific actions required for each patient.

Submit directly to CMS

Submit data across the four performance categories to CMS via the Able Health Qualified Registry. When you track performance throughout the year, end-of-year reporting becomes a simpler—and cheaper—task.

Quality Measures for General Oncology

Able Health can calculate and submit all registry measures in the General Oncology specialty-specific measure set, which are listed below.

Click here to view all MIPS measures across the Quality, Advancing Care Information, and Improvement Activities performance categories

ID Name Type High Priority
047 Care Plan Process Yes
374 Closing the Referral Loop: Receipt of Specialist Report Process Yes
130 Documentation of Current Medications in the Medical Record Process Yes
449 HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies Process Yes
451 KRAS Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy Process No
143 Oncology: Medical and Radiation - Pain Intensity Quantified Process Yes
452 Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies Process Yes
317 Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented Process No
226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention Process No
431 Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling Process No
457 Proportion Admitted to Hospice for less than 3 days Outcome Yes
455 Proportion Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life Outcome Yes
456 Proportion Not Admitted To Hospice Process Yes
454 Proportion of Patients who Died from Cancer with more than One Emergency Department Visit in the Last 30 Days of Life Outcome Yes
453 Proportion Receiving Chemotherapy in the Last 14 Days of Life Process Yes
102 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients Process Yes
250 Radical Prostatectomy Pathology Reporting Process No
402 Tobacco Use and Help with Quitting Among Adolescents Process No
450 Trastuzumab Received By Patients With AJCC Stage I (T1c) - III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy Process Yes

Select a Different Specialty

Select your specialty to find MIPS measures supported by Able Health relevant to your specialty.